We observed a stark disconnect between ICOS and ICOSLG gene expression across several cancers, suggesting a potential mechanism for regulating ICOS costimulation within the TME by using an ICOS agonist mAb when ICOS-L expression is comparatively low, and underscoring the untapped potential of ICOS signaling in cancer. Here, ICOS is linked to cancer.